1. FrascaD. Several areas of overlap between obesity and aging indicate obesity as a biomarker of accelerated aging of human B cell function and antibody responses. Immun Ageing 2022;19:48.
2. BoutariC, MantzorosCS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 2022;133:155217.
3. GoldenA. Obesit’s impact. Nurs Clin North Am 2021;56:xiii-xiv.
4. Afshin A, Forouzanfar MH, Reitsma MB, et al; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.
5. SchnabelF, KornakU, WollnikB. Premature aging disorders: a clinical and genetic compendium. Clin Genet 2021;99:3-28.
6. United Nations, Department of Economic and Social Affairs Population Division. World Population Prospects 2022: Summary of Results. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf. [Last accessed on 15 May 2024].
7. LiX, CaoX, ZhangJ, et al. Accelerated aging mediates the associations of unhealthy lifestyles with cardiovascular disease, cancer, and mortality. J Am Geriatr Soc 2024;72:181-93.
8. RudnickaE, NapierałaP, PodfigurnaA, MęczekalskiB, SmolarczykR, GrymowiczM. The World Health Organization (WHO) approach to healthy ageing. Maturitas 2020;139:6-11.
9. KennedyBK, BergerSL, BrunetA, et al. Geroscience: linking aging to chronic disease. Cell 2014;159:709-13.
10. LiZ, ZhangZ, RenY, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology 2021;22:165-87.
11. XueQL. The frailty syndrome: definition and natural history. Clin Geriatr Med 2011;27:1-15.
12. López-OtínC, BlascoMA, PartridgeL, SerranoM, KroemerG. The hallmarks of aging. Cell 2013;153:1194-217.
13. López-OtínC, BlascoMA, PartridgeL, SerranoM, KroemerG. Hallmarks of aging: an expanding universe. Cell 2023;186:243-78.
14. Global BMI Mortality Collaboration; Di Angelantonio E, Bhupathiraju ShN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86.
15. LungT, JanS, TanEJ, KilledarA, HayesA. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes 2019;43:782-9.
16. FontaineKR, ReddenDT, WangC, WestfallAO, AllisonDB. Years of life lost due to obesity. JAMA 2003;289:187-93.
17. RuzeR, LiuT, ZouX, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol 2023;14:1161521.
18. KolbR, SutterwalaFS, ZhangW. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 2016;29:77-89.
19. DikaiouP, BjörckL, AdielsM, et al. Obesity, overweight and risk for cardiovascular disease and mortality in young women. Eur J Prev Cardiol 2021;28:1351-9.
20. LeeTH, YauSY. From obesity to hippocampal neurodegeneration: pathogenesis and non-pharmacological interventions. Int J Mol Sci 2020;22:201.
21. CaballeroB. Humans against obesity: who will win? Adv Nutr 2019;10:S4-9.
22. TamBT, MoraisJA, SantosaS. Obesity and ageing: two sides of the same coin. Obes Rev 2020;21:e12991.
23. Reyes-FariasM, Fos-DomenechJ, SerraD, HerreroL, Sánchez-InfantesD. White adipose tissue dysfunction in obesity and aging. Biochem Pharmacol 2021;192:114723.
24. ShindeAB, SongA, WangQA. Brown adipose tissue heterogeneity, energy metabolism, and beyond. Front Endocrinol 2021;12:651763.
25. LiQOY, Soro-ArnaizI, AragonésJ. Age-dependent obesity and mitochondrial dysfunction. Adipocyte 2017;6:161-6.
26. ZhangYX, OuMY, YangZH, SunY, LiQF, ZhouSB. Adipose tissue aging is regulated by an altered immune system. Front Immunol 2023;14:1125395.
27. ManK, KalliesA, VasanthakumarA. Resident and migratory adipose immune cells control systemic metabolism and thermogenesis. Cell Mol Immunol 2022;19:421-31.
28. KawaiT, AutieriMV, ScaliaR. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021;320:C375-91.
29. XuC, MathewsAE, RodriguesC, et al. Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN 2018;24:148-55.
30. HotamisligilGS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017;542:177-85.
31. YuL, ChenY, ToozeSA. Autophagy pathway: cellular and molecular mechanisms. Autophagy 2018;14:207-15.
32. AmanY, Schmauck-MedinaT, HansenM, et al. Autophagy in healthy aging and disease. Nat Aging 2021;1:634-50.
33. fa*ghfouriAH, KhajebishakY, PayahooL, fa*ghfuriE, AlivandM. PPAR-gamma agonists: potential modulators of autophagy in obesity. Eur J Pharmacol 2021;912:174562.
34. KalinkovichA, Livsh*tsG. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev 2017;35:200-21.
35. WeiS, NguyenTT, ZhangY, RyuD, GarianiK. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol 2023;14:1185221.
36. BatsisJA, VillarealDT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018;14:513-37.
37. PolyzosSA, MargiorisAN. Sarcopenic obesity. Hormones 2018;17:321-31.
38. WagenaarCA, DekkerLH, NavisGJ. Prevalence of sarcopenic obesity and sarcopenic overweight in the general population: the lifelines cohort study. Clin Nutr 2021;40:4422-9.
39. GaoQ, MeiF, ShangY, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr 2021;40:4633-41.
40. DoniniLM, BusettoL, BischoffSC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 2022;15:321-35.
41. LimS, KimJH, YoonJW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652-4.
42. CrooksB, StamatakiNS, McLaughlinJT. Appetite, the enteroendocrine system, gastrointestinal disease and obesity. Proc Nutr Soc 2021;80:50-8.
43. WestfallS, LomisN, KahouliI, DiaSY, SinghSP, PrakashS. Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cell Mol Life Sci 2017;74:3769-87.
44. JandhyalaSM, TalukdarR, SubramanyamC, VuyyuruH, SasikalaM, NageshwarReddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787-803.
45. O'toolePW, ClaessonMJ. Gut microbiota: Changes throughout the lifespan from infancy to elderly. Int Dairy J 2010;20:281-91.
46. BäckhedF, ManchesterJK, sem*nkovichCF, GordonJI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007;104:979-84.
47. RinninellaE, TohumcuE, RaoulP, et al. The role of diet in shaping human gut microbiota. Best Pract Res Clin Gastroenterol 2023;62-63:101828.
48. HasanN, YangH. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019;7:e7502.
49. LiuBN, LiuXT, LiangZH, WangJH. Gut microbiota in obesity. World J Gastroenterol 2021;27:3837-50.
50. LingZ, LiuX, ChengY, YanX, WuS. Gut microbiota and aging. Crit Rev Food Sci Nutr 2022;62:3509-34.
51. StojanovS, BerlecA, ŠtrukeljB. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms 2020;8:1715.
52. DeJongEN, SuretteMG, BowdishDME. The gut microbiota and unhealthy aging: disentangling cause from consequence. Cell Host Microbe 2020;28:180-9.
53. TurnbaughPJ, HamadyM, YatsunenkoT, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4.
54. AounA, DarwishF, HamodN. The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss. Prev Nutr Food Sci 2020;25:113-23.
55. MagneF, GottelandM, GauthierL, et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients 2020;12:1474.
56. CastanerO, GodayA, ParkYM, et al. The gut microbiome profile in obesity: a systematic review. Int J Endocrinol 2018;2018:4095789.
57. PetersBA, ShapiroJA, ChurchTR, et al. A taxonomic signature of obesity in a large study of American adults. Sci Rep 2018;8:9749.
58. KoutoukidisDA, JebbSA, ZimmermanM, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes 2022;14:2020068.
59. VazM, PereiraSS, MonteiroMP. Metabolomic signatures after bariatric surgery - a systematic review. Rev Endocr Metab Disord 2022;23:503-19.
60. TavassolZH, EjtahedHS, AtlasiR, et al. Alteration in gut microbiota composition of older adults is associated with obesity and its indices: a systematic review. J Nutr Health Aging 2023;27:817-23.
61. KesaveluD, JogP. Current understanding of antibiotic-associated dysbiosis and approaches for its management. Ther Adv Infect Dis 2023;10:20499361231154443.
62. MalikJA, ZafarMA, LambaT, NandaS, KhanMA, AgrewalaJN. The impact of aging-induced gut microbiome dysbiosis on dendritic cells and lung diseases. Gut Microbes 2023;15:2290643.
63. HungCC, ChangCC, HuangCW, NouchiR, ChengCH. Gut microbiota in patients with Alzheimer’s disease spectrum: a systematic review and meta-analysis. Aging 2022;14:477-96.
64. AlmeidaHM, SardeliAV, ConwayJ, DuggalNA, CavaglieriCR. Comparison between frail and non-frail older adults’ gut microbiota: a systematic review and meta-analysis. Ageing Res Rev 2022;82:101773.
65. PalmasV, PisanuS, MadauV, et al. Gut microbiota markers and dietary habits associated with extreme longevity in healthy sardinian centenarians. Nutrients 2022;14:2436.
66. BiagiE, FranceschiC, RampelliS, et al. Gut microbiota and extreme longevity. Curr Biol 2016;26:1480-5.
67. LuanZ, SunG, HuangY, et al. Metagenomics study reveals changes in gut microbiota in centenarians: a cohort study of Hainan centenarians. Front Microbiol 2020;11:1474.
68. SeppE, SmidtI, RööpT, et al. Comparative analysis of gut microbiota in centenarians and young people: impact of eating habits and childhood living environment. Front Cell Infect Microbiol 2022;12:851404.
69. PangS, ChenX, LuZ, et al. Longevity of centenarians is reflected by the gut microbiome with youth-associated signatures. Nat Aging 2023;3:436-49.
70. ZhangS, ZengB, ChenY, et al. Gut microbiota in healthy and unhealthy long-living people. Gene 2021;779:145510.
71. WilmanskiT, DienerC, RappaportN, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab 2021;3:274-86.
72. KaperJB, NataroJP, MobleyHLT. Pathogenic Escherichia coli. Nat Rev Microbiol 2004;2:123-40.
73. MohammadS, ThiemermannC. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol 2020;11:594150.
74. GhoshS, LertwattanarakR, GarduñoJde J, et al. Elevated muscle TLR4 expression and metabolic endotoxemia in human aging. J Gerontol A Biol Sci Med Sci 2015;70:232-46.
75. FranceschiC, GaragnaniP, PariniP, GiulianiC, SantoroA. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14:576-90.
76. CrovesyL, MastersonD, RosadoEL. Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr 2020;74:1251-62.
77. Vatanen T, Kostic AD, d’Hennezel E, et al; DIABIMMUNE Study Group. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016;165:842-53.
78. AhmadR, RahB, BastolaD, DhawanP, SinghAB. Obesity-induces organ and tissue specific tight junction restructuring and barrier deregulation by claudin switching. Sci Rep 2017;7:5125.
79. NagpalR, NewmanTM, WangS, JainS, LovatoJF, YadavH. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res 2018;2018:3462092.
80. YaoD, DaiW, DongM, DaiC, WuS. MUC2 and related bacterial factors: therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751.
81. HussainM, UmairIjaz M, AhmadMI, et al. Meat proteins in a high-fat diet have a substantial impact on intestinal barriers through mucus layer and tight junction protein suppression in C57BL/6J mice. Food Funct 2019;10:6903-14.
82. GhoshTS, ShanahanF, O'ToolePW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol 2022;19:565-84.
83. WuM, WuY, LiJ, et al. The dynamic changes of gut microbiota in Muc2 deficient mice. Int J Mol Sci 2018;19:2809.
84. ChenZ, LuoJ, LiJ, et al. Foxo1 controls gut homeostasis and commensalism by regulating mucus secretion. J Exp Med 2021:218.
85. TranL, Greenwood-VanMeerveld B. Age-associated remodeling of the intestinal epithelial barrier. J Gerontol A Biol Sci Med Sci 2013;68:1045-56.
86. OamiT, AbtahiS, ShimazuiT, et al. Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. Proc Natl Acad Sci U S A 2024;121:e2217877121.
87. Cuevas-SierraA, Ramos-LopezO, Riezu-BojJI, MilagroFI, MartinezJA. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. Adv Nutr 2019;10:S17-30.
88. AnachadO, TaouilA, TahaW, BennisF, ChegdaniF. The implication of short-chain fatty acids in obesity and diabetes. Microbiol Insights 2023;16:11786361231162720.
89. WaltersWA, XuZ, KnightR. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett 2014;588:4223-33.
90. Ecklu-MensahG, Choo-KangC, MasengMG, et al. Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study. Nat Commun 2023;14:5160.
91. dela Cuesta-Zuluaga J, MuellerNT, Álvarez-QuinteroR, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients 2018;11:51.
92. RampelliS, CandelaM, TurroniS, et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging 2013;5:902-12.
93. JonesML, MartoniCJ, GanopolskyJG, LabbéA, PrakashS. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opin Biol Ther 2014;14:467-82.
94. FrommherzL, BubA, HummelE, et al. Age-related changes of plasma bile acid concentrations in healthy adults--results from the cross-sectional KarMeN study. PLoS One 2016;11:e0153959.
95. BadalVD, VaccarielloED, MurrayER, et al. The gut microbiome, aging, and longevity: a systematic review. Nutrients 2020;12:3759.
96. HersougLG, MøllerP, LoftS. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. Nutr Res Rev 2018;31:153-63.
97. ShiH, KokoevaMV, InouyeK, TzameliI, YinH, FlierJS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25.
98. GhoshAK, O'BrienM, MauT, YungR. Toll-like receptor 4 (TLR4) deficient mice are protected from adipose tissue inflammation in aging. Aging 2017;9:1971-82.
99. TilvesCM, ZmudaJM, KuipersAL, et al. Association of lipopolysaccharide-binding protein with aging-related adiposity change and prediabetes among African ancestry men. Diabetes Care 2016;39:385-91.
100. LiuX, LuL, YaoP, et al. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese. Diabetologia 2014;57:1834-41.
101. GomesJMG, CostaJA, AlfenasRCG. Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism 2017;68:133-44.
102. KavanaghK, HsuFC, DavisAT, KritchevskySB, RejeskiWJ, KimS. Biomarkers of leaky gut are related to inflammation and reduced physical function in older adults with cardiometabolic disease and mobility limitations. Geroscience 2019;41:923-33.
103. BrownGC. The endotoxin hypothesis of neurodegeneration. J Neuroinflammation 2019;16:180.
104. MarizzoniM, CattaneoA, MirabelliP, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer’s disease. J Alzheimers Dis 2020;78:683-97.
105. KesikaP, SuganthyN, SivamaruthiBS, ChaiyasutC. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sci 2021;264:118627.
106. LawrenceJM, SchardienK, WigdahlB, NonnemacherMR. Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathol Commun 2023;11:42.
107. Serrano-PozoA, MuzikanskyA, Gómez-IslaT, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 2013;72:462-71.
108. AhmadMH, FatimaM, MondalAC. Role of hypothalamic-pituitary-adrenal axis, hypothalamic-pituitary-gonadal axis and insulin signaling in the pathophysiology of Alzheimer’s disease. Neuropsychobiology 2019;77:197-205.
109. WerdermannM, BergerI, ScribaLD, et al. Insulin and obesity transform hypothalamic-pituitary-adrenal axis stemness and function in a hyperactive state. Mol Metab 2021;43:101112.
110. BrowningKN, VerheijdenS, BoeckxstaensGE. The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology 2017;152:730-44.
111. SenT, CawthonCR, IhdeBT, et al. Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. Physiol Behav 2017;173:305-17.
112. PhillipsRJ, WalterGC, PowleyTL. Age-related changes in vagal afferents innervating the gastrointestinal tract. Auton Neurosci 2010;153:90-8.
113. HanY, WangB, GaoH, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. J Inflamm Res 2022;15:6213-30.
114. MarshSE, Blurton-JonesM. Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther 2012;4:11.
115. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22:1-203.
116. Hernández-ReyesA, Cámara-MartosF, Molina-LuqueR, Romero-SaldañaM, Molina-RecioG, Moreno-RojasR. Changes in body composition with a hypocaloric diet combined with sedentary, moderate and high-intense physical activity: a randomized controlled trial. BMC Womens Health 2019;19:167.
117. ChaoAM, QuigleyKM, WaddenTA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest 2021;131:140065.
118. DiRosa C, LattanziG, SpieziaC, et al. Mediterranean diet versus very low-calorie ketogenic diet: effects of reaching 5% body weight loss on body composition in subjects with overweight and with obesity-a cohort study. Int J Environ Res Public Health 2022;19:13040.
119. BruciA, TuccinardiD, TozziR, et al. Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure. Nutrients 2020;12:333.
120. DongTS, LuuK, LagishettyV, et al. A high protein calorie restriction diet alters the gut microbiome in obesity. Nutrients 2020;12:3221.
121. TettamanziF, BagnardiV, LoucaP, et al. A high protein diet is more effective in improving insulin resistance and glycemic variability compared to a mediterranean diet-a cross-over controlled inpatient dietary study. Nutrients 2021;13:4380.
122. KheniserK, SaxonDR, KashyapSR. Long-term weight loss strategies for obesity. J Clin Endocrinol Metab 2021;106:1854-66.
123. MachadoAM, GuimarãesNS, BocardiVB, et al. Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis. Clin Nutr ESPEN 2022;49:138-53.
124. JacksonVM, BreenDM, FortinJP, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discov 2015;10:825-39.
125. Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol 2019;15:274-87.
126. PerryAS, TanriverdiK, RisitanoA, et al. The inflammatory proteome, obesity, and medical weight loss and regain in humans. Obesity 2023;31:150-8.
127. FitzgeraldKN, HodgesR, HanesD, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging 2021;13:9419-32.
128. WaziryR, RyanCP, CorcoranDL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging 2023;3:248-57.
129. LiljaS, StollC, KrammerU, et al. Five days periodic fasting elevates levels of longevity related christensenella and sirtuin expression in humans. Int J Mol Sci 2021;22:2331.
130. McGrattanAM, McGuinnessB, McKinleyMC, et al. Diet and inflammation in cognitive ageing and Alzheimer’s disease. Curr Nutr Rep 2019;8:53-65.
131. FilippouCD, TsioufisCP, Thom*opoulosCG, et al. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2020;11:1150-60.
132. ElsayedMM, RabieeA, ElRefaye GE, ElsisiHF. Aerobic exercise with mediterranean-DASH intervention for neurodegenerative delay diet promotes brain cells’ longevity despite sex hormone deficiency in postmenopausal women: a randomized controlled trial. Oxid Med Cell Longev 2022;2022:4146742.
133. LiuX, MorrisMC, DhanaK, et al. Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) study: rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline. Contemp Clin Trials 2021;102:106270.
134. Office for Health Improvement & Disparities. A consensus on healthy ageing. Available from: https://www.gov.uk/government/publications/healthy-ageing-consensus-statement/a-consensus-on-healthy-ageing. [Last accessed on 15 May 2024].
135. LegrandR, NuemiG, PoulainM, ManckoundiaP. Description of lifestyle, including social life, diet and physical activity, of people ≥ 90 years living in Ikaria, a longevity blue zone. Int J Environ Res Public Health 2021;18:6602.
136. FastameMC. Well-being, food habits, and lifestyle for longevity. Preliminary evidence from the sardinian centenarians and long-lived people of the Blue Zone. Psychol Health Med 2022;27:728-33.
137. ZhangH, ShiN, DiaoZ, ChenY, ZhangY. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: past and future. Genes Dis 2021;8:38-47.
138. ScioratiC, GamberaleR, MonnoA, et al. Pharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice. Aging 2020;12:23497-508.
139. AmorC, Fernández-MaestreI, ChowdhuryS, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging 2024;4:336-49.
140. AvcıA, AvcıD, UlaşY, ErtaşR. Can biologic agents improve treatment success in obese patients with psoriasis vulgaris: a retrospective review of 320 patients with psoriasis vulgaris. Dermatol Pract Concept 2024;14:e2024058.
141. AnghelF, NituscaD, CristodorP. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis. Life 2021;11:1316.
142. PatsalosO, DaltonB, LeppanenJ, IbrahimMAA, HimmerichH. Impact of TNF-α inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol 2020;11:481.
143. BarrosG, DuranP, VeraI, BermúdezV. Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci 2022;23:7499.
144. Grunvald E, Shah R, Hernaez R, et al; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163:1198-225.
145. ChakhtouraM, HaberR, GhezzawiM, RhayemC, TcheroyanR, MantzorosCS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine 2023;58:101882.
146. GiruzziN. Plenity (oral superabsorbent hydrogel). Clin Diabetes 2020;38:313-4.
147. SuranM. As ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. JAMA 2023;329:1627-9.
148. HanSH, SafeekR, OckermanK, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a google trends analysis. Aesthet Surg J 2023;44:60-7.
149. ZhangY, LiQ, NiuY, et al. Research progress on aging mechanism and drugs and the role of stem cells in anti-aging process. Exp Gerontol 2023;179:112248.
150. MohammedI, HollenbergMD, DingH, TriggleCR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol 2021;12:718942.
151. CampbellJM, BellmanSM, StephensonMD, LisyK. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev 2017;40:31-44.
152. U.S. Food and Drug Administration. GLUCOPHAGE® (metformin hydrochloride) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf. [Last accessed on 15 May 2024].
153. LaMoiaTE, ShulmanGI. Cellular and molecular mechanisms of metformin action. Endocr Rev 2021;42:77-96.
154. KulkarniAS, BrutsaertEF, AnghelV, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell 2018;17:e12723.
155. U.S. Food and Drug Administration. Rapamune (sirolimus) Label. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf. [Last accessed on 15 May 2024].
156. JuricicP, LuYX, LeechT, et al. Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy. Nat Aging 2022;2:824-36.
157. KulkarniAS, AleksicS, BergerDM, SierraF, KuchelGA, BarzilaiN. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization. Aging Cell 2022;21:e13596.
158. ErshadM, NajiA, VearrierD. N-acetylcysteine. Treasure island (FL): StatPearls Publishing; 2024.
159. SohouliMH, EslamianG, MalekpourAlamdari N, et al. Effects of N-acetylcysteine on aging cell and obesity complications in obese adults: a randomized, double-blind clinical trial. Front Nutr 2023;10:1237869.
160. U.S. Food and Drug Administration. SprycelTM (dasatinib) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986s000_Sprycel__PRNTLBL.pdf. [Last accessed on 15 May 2024].
161. ZhangL, PitcherLE, YousefzadehMJ, NiedernhoferLJ, RobbinsPD, ZhuY. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest 2022;132:e158450.
162. ScarpelliniE, RinninellaE, BasilicoM, et al. From pre- and probiotics to post-biotics: a narrative review. Int J Environ Res Public Health 2021;19:37.
163. SlavinJ. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013;5:1417-35.
164. GreenM, AroraK, PrakashS. Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci 2020;21:2890.
165. Davani-DavariD, NegahdaripourM, KarimzadehI, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 2019;8:92.
166. CanforaEE, vander Beek CM, HermesGDA, et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 2017;153:87-97.e3.
167. ArnoldJW, RoachJ, FabelaS, et al. The pleiotropic effects of prebiotic galacto-oligosaccharides on the aging gut. Microbiome 2021;9:31.
168. QiangX, YonglieC, QianbingW. Health benefit application of functional oligosaccharides. Carbohydr Polym 2009;77:435-41.
169. MaC, YangK, WangY, DaiX. Anti-aging effect of agar oligosaccharide on male drosophila melanogaster and its preliminary mechanism. Mar Drugs 2019;17:632.
170. D’AndreaG. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 2015;106:256-71.
171. JungCH, ChoI, AhnJ, JeonTI, HaTY. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res 2013;27:139-43.
172. CuiZ, ZhaoX, AmevorFK, et al. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front Immunol 2022;13:943321.
173. SacconTD, NagpalR, YadavH, et al. Senolytic combination of dasatinib and quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice. J Gerontol A Biol Sci Med Sci 2021;76:1895-905.
174. GonzalesMM, GarbarinoVR, MarquesZilli E, et al. Senolytic therapy to modulate the progression of Alzheimer’s disease (SToMP-AD): a pilot clinical trial. J Prev Alzheimers Dis 2022;9:22-9.
175. ZhaoL, ZhuX, XiaM, et al. Quercetin ameliorates gut microbiota dysbiosis that drives hypothalamic damage and hepatic lipogenesis in monosodium glutamate-induced abdominal obesity. Front Nutr 2021;8:671353.
176. sh*t, BianX, YaoZ, WangY, GaoW, GuoC. Quercetin improves gut dysbiosis in antibiotic-treated mice. Food Funct 2020;11:8003-13.
177. YuanH, LiY, LingF, et al. The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats. Aging Cell 2020;19:e13199.
178. HuangLH, LiuCY, WangLY, HuangCJ, HsuCH. Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial. BMC Complement Altern Med 2018;18:294.
179. D'AmicoD, OlmerM, FouassierAM, et al. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging Cell 2022;21:e13662.
180. KongS, HuangX, CaoH, et al. Anti-obesity effects of galacto-oligosaccharides in obese rats. Eur J Pharmacol 2022;917:174728.
181. KrumbeckJA, RasmussenHE, HutkinsRW, et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome 2018;6:121.
182. HillC, GuarnerF, ReidG, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.
183. KechagiaM, BasoulisD, KonstantopoulouS, et al. Health benefits of probiotics: a review. ISRN Nutr 2013;2013:481651.
184. SinghRK, ChangHW, YanD, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017;15:73.
185. TsaiYC, ChengLH, LiuYW, JengOJ, LeeYK. Gerobiotics: probiotics targeting fundamental aging processes. Biosci Microbiota Food Health 2021;40:1-11.
186. Tomaro-duch*esneauC, SahaS, MalhotraM, et al. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl Microbiol Biotechnol 2014;98:115-26.
187. WestfallS, LomisN, PrakashS. A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in Drosophila. J Funct Foods 2018;48:374-86.
188. IqbalUH, WestfallS, PrakashS. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artif Cells Nanomed Biotechnol 2018;46:S116-24.
189. LeeE, JungSR, LeeSY, LeeNK, PaikHD, LimSI. Lactobacillus plantarum strain Ln4 attenuates diet-induced obesity, insulin resistance, and changes in hepatic mRNA levels associated with glucose and lipid metabolism. Nutrients 2018;10:643.
190. van BeekAA, SovranB, HugenholtzF, et al. Supplementation with Lactobacillus plantarum WCFS1 prevents decline of mucus barrier in colon of accelerated aging Ercc1-/Δ7 mice. Front Immunol 2016;7:408.
191. LeeCC, LiaoYC, LeeMC, et al. Lactobacillus plantarum TWK10 attenuates aging-associated muscle weakness, bone loss, and cognitive impairment by modulating the gut microbiome in mice. Front Nutr 2021;8:708096.
192. KangY, KangX, YangH, et al. Lactobacillus acidophilus ameliorates obesity in mice through modulation of gut microbiota dysbiosis and intestinal permeability. Pharmacol Res 2022;175:106020.
193. VallianouN, StratigouT, ChristodoulatosGS, TsigalouC, DalamagaM. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr Obes Rep 2020;9:179-92.
194. JangAY, Rod-InW, MonmaiC, et al. Anti-inflammatory potential of Lactobacillus reuteri LM1071 via eicosanoid regulation in LPS-stimulated RAW264.7 cells. J Appl Microbiol 2022;133:67-75.
195. DiasAMM, DouhardR, HermetetF, et al. Lactobacillus stress protein GroEL prevents colonic inflammation. J Gastroenterol 2021;56:442-55.
196. MuQ, TavellaVJ, LuoXM. Role of Lactobacillus reuteri in human health and diseases. Front Microbiol 2018;9:757.
197. JonesML, MartoniCJ, PrakashS. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating
198. Tenorio-JiménezC, Martínez-RamírezMJ, Tercero-LozanoM, et al. Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR). BMC Complement Altern Med 2018;18:306.
199. MillionM, AngelakisE, MaraninchiM, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes 2013;37:1460-6.
200. Álvarez-ArrañoV, Martín-PeláezS. Effects of probiotics and synbiotics on weight loss in subjects with overweight or obesity: a systematic review. Nutrients 2021;13:3627.
201. ChenLH, ChangSS, ChangHY, et al. Probiotic supplementation attenuates age-related sarcopenia via the gut-muscle axis in SAMP8 mice. J Cachexia Sarcopenia Muscle 2022;13:515-31.
202. ChengLH, ChouPY, HouAT, HuangCL, ShiuWL, WangS. Lactobacillus paracasei PS23 improves cognitive deficits via modulating the hippocampal gene expression and the gut microbiota in D-galactose-induced aging mice. Food Funct 2022;13:5240-51.
203. ChenLH, HuangSY, HuangKC, et al. Lactobacillus paracasei PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice. Aging 2019;11:756-70.
204. CorpuzHM, IchikawaS, ArimuraM, et al. Long-term diet supplementation with Lactobacillus paracasei K71 Prevents age-related cognitive decline in senescence-accelerated mouse prone 8. Nutrients 2018;10:762.
205. Moro-GarcíaMA, Alonso-AriasR, BaltadjievaM, et al. Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects. Age 2013;35:1311-26.
206. AbdelhamidAG, El-MasrySS, El-DougdougNK. Probiotic Lactobacillus and Bifidobacterium strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. EPMA J 2019;10:337-50.
207. LeeSY, LeeBH, ParkJH, ParkMS, JiGE, SungMK. Bifidobacterium bifidum BGN4 paraprobiotic supplementation alleviates experimental colitis by maintaining gut barrier and suppressing nuclear factor kappa B activation signaling molecules. J Med Food 2022;25:146-57.
208. MarrasL, CaputoM, BisicchiaS, et al. The role of bifidobacteria in predictive and preventive medicine: a focus on eczema and hypercholesterolemia. Microorganisms 2021;9:836.
209. RahmanMS, LeeY, ParkDS, KimYS. Bifidobacterium bifidum DS0908 and Bifidobacterium longum DS0950 culture-supernatants ameliorate obesity-related characteristics in mice with high-fat diet-induced obesity. J Microbiol Biotechnol 2023;33:96-105.
210. WangJ, QieJ, ZhuD, et al. The landscape in the gut microbiome of long-lived families reveals new insights on longevity and aging - relevant neural and immune function. Gut Microbes 2022;14:2107288.
211. MoSJ, LeeK, HongHJ, et al. Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on overweight and the gut microbiota in humans: randomized, double-blinded, placebo-controlled clinical trial. Nutrients 2022;14:2484.
212. SohnM, NaGY, ChuJ, JoungH, KimBK, LimS. Efficacy and safety of Lactobacillus plantarum K50 on lipids in Koreans with obesity: a randomized, double-blind controlled clinical trial. Front Endocrinol 2021;12:790046.
213. RahayuES, MariyatunM, PutriManurung NE, et al. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021;27:107-28.
214. MichaelDR, DaviesTS, JackAA, et al. Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults. Sci Rep 2021;11:5.
215. AljumaahMR, BhatiaU, RoachJ, GunstadJ, AzcaratePeril MA. The gut microbiome, mild cognitive impairment, and probiotics: a randomized clinical trial in middle-aged and older adults. Clin Nutr 2022;41:2565-76.
216. HwangYH, ParkS, PaikJW, et al. Efficacy and safety of Lactobacillus plantarum C29-Fermented Soybean (DW2009) in individuals with mild cognitive impairment: a 12-week, multi-center, randomized, double-blind, placebo-controlled clinical trial. Nutrients 2019;11:305.
217. KimCS, ChaL, SimM, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci 2021;76:32-40.
218. AsaokaD, XiaoJ, TakedaT, et al. Effect of probiotic bifidobacterium breve in improving cognitive function and preventing brain atrophy in older patients with suspected mild cognitive impairment: results of a 24-week randomized, double-blind, placebo-controlled trial. J Alzheimers Dis 2022;88:75-95.
219. FeiY, WangR, LuJ, et al. Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment. Geriatr Nurs 2023;51:167-75.
220. ShiS, ZhangQ, SangY, et al. Probiotic Bifidobacterium longum BB68S improves cognitive functions in healthy older adults: a randomized, double-blind, placebo-controlled trial. Nutrients 2022;15:51.
221. BorgesMK, deCastro Cezar NO, SantosSiqueira AS, YassudaM, CesariM, AprahamianI. The relationship between physical frailty and mild cognitive impairment in the elderly: a systematic review. J Frailty Aging 2019;8:192-7.
222. Quintero DF, Kok CR, Hutkins R. The future of synbiotics: rational formulation and design. Front Microbiol 2022;13:919725.
223. WestfallS, LomisN, PrakashS. Longevity extension in Drosophila through gut-brain communication. Sci Rep 2018;8:8362.
224. SergeevIN, AljutailyT, WaltonG, HuarteE. Effects of synbiotic supplement on human gut microbiota, body composition and weight loss in obesity. Nutrients 2020;12:222.
225. TrippML, DahlbergCJ, EliasonS, et al. A low-glycemic, mediterranean diet and lifestyle modification program with targeted nutraceuticals reduces body weight, improves cardiometabolic variables and longevity biomarkers in overweight subjects: a 13-week observational trial. J Med Food 2019;22:479-89.
226. KoppL, SchweinlinA, TingöL, et al. Potential modulation of inflammation and physical function by combined probiotics, omega-3 supplementation and vitamin d supplementation in overweight/obese patients with chronic low-grade inflammation: a randomized, placebo-controlled trial. Int J Mol Sci 2023;24:8567.
227. SarosL, VahlbergT, KoivuniemiE, et al. Fish oil and/or probiotics intervention in overweight/obese pregnant women and overweight risk in 24-month-old children. J Pediatr Gastroenterol Nutr 2023;76:218-26.
228. FordAL, NagulesapillaiV, PianoA, et al. Microbiota stability and gastrointestinal tolerance in response to a high-protein diet with and without a prebiotic, probiotic, and synbiotic: a randomized, double-blind, placebo-controlled trial in older women. J Acad Nutr Diet 2020;120:500-16.e10.
229. CrovesyL, El-BachaT, RosadoEL. Modulation of the gut microbiota by probiotics and symbiotics is associated with changes in serum metabolite profile related to a decrease in inflammation and overall benefits to metabolic health: a double-blind randomized controlled clinical trial in women with obesity. Food Funct 2021;12:2161-70.
230. BaştürkA, ArtanR, YılmazA. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol 2016;27:439-43.
231. SalminenS, ColladoMC, EndoA, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol 2021;18:649-67.
232. LuY, FanC, LiP, LuY, ChangX, QiK. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci Rep 2016;6:37589.
233. HildebrandCB, LichatzR, PichA, et al. Short-chain fatty acids improve inflamm-aging and acute lung injury in old mice. Am J Physiol Lung Cell Mol Physiol 2023;324:L480-92.
234. AroraK, GreenM, PrakashS. The microbiome and Alzheimer’s disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. Front Bioeng Biotechnol 2020;8:537847.
235. KahouliI, MalhotraM, Tomaro-duch*esneauC, RodesLS, Alaoui-JamaliMA, PrakashS. Identification of Lactobacillus Fermentum strains with potential against colorectal cancer by characterizing short chain fatty acids production, anti-proliferative activity and survival in an intestinal fluid: in vitro analysis. J Bioanal Biomed 2015;7:4. Available from: https://hal.science/hal-04021382v1/file/identification-of-lactobacillus-fermentum-strains-with-potential-against-colorectal-cancer-by-characterizing-1948-593X-1000132.pdf. [Last accessed on 15 May 2024]
236. WestfallS, LomisN, SinghSP, PrakashS. Ferulic acid produced by Lactobacillus fermentum NCIMB 5221 reduces symptoms of metabolic syndrome in Drosophila melanogaster. J Microb Biochem Technol 2016;8:4.
237. deMelo TS, LimaPR, CarvalhoKM, et al. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. Braz J Med Biol Res 2017;50:e5630.
238. DiNicolantonioJJ, McCartyMF, AssangaSI, LujanLL, O’KeefeJH. Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity. Open Heart 2022;9:e001801.
239. FogelsonKA, DorresteinPC, ZarrinparA, KnightR. The gut microbial bile acid modulation and its relevance to digestive health and diseases. Gastroenterology 2023;164:1069-85.
240. PreteR, LongSL, GallardoAL, GahanCG, CorsettiA, JoyceSA. Beneficial bile acid metabolism from Lactobacillus plantarum of food origin. Sci Rep 2020;10:1165.
241. MazloomK, SiddiqiI, CovasaM. Probiotics: how effective are they in the fight against obesity? Nutrients 2019;11:258.
242. Pérez-RamosA, Madi-MoussaD, CoucheneyF, DriderD. Current knowledge of the mode of action and immunity mechanisms of LAB-bacteriocins. Microorganisms 2021;9:2107.
243. AhmadW, BoyajianJL, AbosalhaA, et al. High-molecular-weight dextran-type exopolysaccharide produced by the novel Apilactobacillus waqarii improves metabolic syndrome: in vitro and in vivo analyses. Int J Mol Sci 2022;23:12692.
244. LimJ, KaleM, KimDH, et al. Antiobesity effect of exopolysaccharides isolated from kefir grains. J Agric Food Chem 2017;65:10011-9.
245. ZhangJ, ZhaoX, JiangY, et al. Antioxidant status and gut microbiota change in an aging mouse model as influenced by exopolysaccharide produced by Lactobacillus plantarum YW11 isolated from Tibetan kefir. J Dairy Sci 2017;100:6025-41.
